Alkaline phosphatase — commonly abbreviated ALP — is an enzyme measured as part of the standard liver function panel that provides unique diagnostic information about conditions affecting the liver, bile ducts, and bones that the aminotransferases ALT and AST cannot provide. While ALT and AST primarily signal hepatocellular injury, ALP elevation points toward a fundamentally different category of pathology: cholestasis (impaired bile flow) and diseases affecting biliary epithelium or bone. Understanding what alkaline phosphatase measures, which tissues produce it, what disease states cause it to rise, and how to interpret its elevation in combination with GGT and the overall liver function panel is essential for any clinician ordering liver blood tests or any patient trying to understand results that show an isolated or predominant ALP elevation. The clinical approach to an elevated ALP is systematically different from the approach to elevated ALT — different conditions, different investigations, and different urgency levels — and this distinction is one of the most practically useful in liver blood test interpretation.
Alkaline phosphatase is not a single enzyme but a family of isoenzymes produced in multiple tissues including the liver (specifically bile duct epithelial cells, cholangiocytes), bone (osteoblasts), placenta, small intestine, and kidneys. This multi-organ origin means that an elevated ALP on a blood panel may arise from hepatic or biliary disease, from bone disease, from pregnancy, or from several other physiological and pathological states — and accurately attributing the elevation to its source is the first step in clinical interpretation. The most important practical tool for attributing ALP elevation to a hepatic versus non-hepatic source is simultaneous GGT measurement: GGT is a sensitive indicator of hepatobiliary pathology and is not elevated by bone disease or pregnancy, so a co-elevated GGT confirms hepatic origin of the ALP elevation, while a normal GGT points toward bone, pregnancy, or other non-hepatic sources.
What Alkaline Phosphatase Measures and Normal Ranges
Normal ALP ranges vary by age, sex, and laboratory, making reference range interpretation context-dependent. In adults, the typical normal range is approximately 30–120 IU/L (though some laboratories use 40–130 IU/L), but this range is derived primarily from populations including pregnant women and older adults — both of whom have physiologically elevated ALP. In children and adolescents, ALP is physiologically two to five times higher than adult ranges due to the contribution of bone isoenzyme from active bone growth (growth plate ossification), peaking at puberty before falling to adult levels in late adolescence. In pregnancy, placental ALP raises total ALP to two to four times the normal adult upper limit in the third trimester without indicating liver or bile duct pathology — and this normal pregnancy-related elevation can falsely suggest hepatobiliary disease if the laboratory reference range doesn’t account for gestational age. In older adults, bone turnover and osteoblastic activity elevate bone ALP isoenzyme modestly, producing mildly elevated ALP in otherwise healthy elderly individuals. These physiological variations reinforce the importance of interpreting any ALP result in the clinical context of the patient’s age, sex, pregnancy status, and concurrent GGT result before drawing diagnostic conclusions.
In hepatobiliary disease specifically, ALP produced by cholangiocytes — the epithelial cells lining the bile ducts — is induced and released when bile flow is obstructed or when bile duct cells are directly inflamed or injured. The mechanism differs from aminotransferase release: rather than leaking from damaged cells (as ALT and AST do), hepatic ALP is actively induced — bile acids and inflammatory mediators upregulate ALP gene expression and membrane release, producing the elevation seen in cholestatic conditions. This induction mechanism means that ALP rises more slowly in acute cholestasis than aminotransferases rise in acute hepatocellular injury, and the degree of ALP elevation does not correlate linearly with the severity of obstruction. A complete bile duct obstruction from a common bile duct stone can produce ALP elevation of only two to three times the upper limit of normal initially, while a slowly developing stricture from primary sclerosing cholangitis may produce higher ALP elevation from chronic induction over time. The article on pale stools as a clinical sign of bile duct obstruction explains the downstream clinical consequences of impaired bile flow that ALP elevation signals.
Hepatic Causes of Elevated ALP — Cholestatic Liver Disease
When ALP elevation is confirmed to be of hepatic origin (by co-elevation of GGT), the clinical differential divides into intrahepatic and extrahepatic cholestatic causes. Extrahepatic biliary obstruction — physical blockage of the bile ducts outside the liver — is the most urgent category to investigate and exclude, as it frequently requires prompt intervention. Choledocholithiasis (stones in the common bile duct, as distinct from gallbladder stones that do not obstruct the duct) is the most common cause of acute extrahepatic biliary obstruction, producing ALP elevation alongside raised GGT and often rising bilirubin; if accompanied by fever and right upper quadrant pain (Charcot’s triad), cholangitis must be excluded as a matter of urgency. Pancreatic head carcinoma obstructing the bile duct is among the most serious causes of elevated ALP — the combination of painless progressive jaundice, markedly elevated ALP and bilirubin, weight loss, and a dilated bile duct on ultrasound should prompt urgent CT imaging of the pancreas and hepatobiliary MRCP. Cholangiocarcinoma (bile duct cancer), ampullary carcinoma, and extrinsic lymph node compression can produce similar presentations with elevated ALP and obstructive jaundice.
Primary biliary cholangitis (PBC) — formerly called primary biliary cirrhosis — is one of the most important intrahepatic cholestatic causes of elevated ALP, and its recognition depends on including it in the differential of any patient (typically a middle-aged woman) with persistently elevated ALP and GGT even in the absence of jaundice. PBC is an autoimmune condition targeting intrahepatic bile duct epithelium, producing progressive inflammation, ductopenia (loss of small bile ducts), and eventually biliary cirrhosis. The diagnosis is made by the combination of elevated ALP (typically two to ten times normal), positive anti-mitochondrial antibody (AMA, positive in over ninety percent of PBC cases), and characteristic liver histology on biopsy if needed. Ursodeoxycholic acid (UDCA) is the established first-line treatment, slowing disease progression and improving long-term outcomes substantially when started before advanced fibrosis develops — making early diagnosis through ALP investigation clinically important. Primary sclerosing cholangitis (PSC) is another important intrahepatic cholestatic condition, associated with inflammatory bowel disease (particularly ulcerative colitis) in approximately seventy-five percent of cases, and characterized by multifocal stricturing and dilation of both intrahepatic and extrahepatic bile ducts visible on MRCP. PSC elevates ALP and GGT and carries a lifetime risk of cholangiocarcinoma of ten to twenty percent, requiring surveillance cholangiography. The article on itchy skin as a symptom of cholestatic liver disease covers the bile salt-mediated pruritus that is a key symptom in both PBC and PSC.
Bone and Non-Hepatic Causes of Elevated ALP
When ALP is elevated with a normal GGT, the hepatobiliary tract is excluded as the source and investigation pivots toward bone and other non-hepatic causes. The most common bone cause of elevated ALP in adults is Paget’s disease of bone — a chronic condition of dysregulated bone remodelling affecting focal regions of the skeleton, with the highest bone ALP values (sometimes twenty to forty times normal) seen in polyostotic disease involving large bones. Paget’s disease may be asymptomatic and discovered incidentally on blood tests, or may present with bone pain, deformity (bowing of long bones), pathological fracture, or neurological compression. Bone metastases — secondary spread of malignancy to bone, particularly from breast, prostate, and lung primaries — produce elevated ALP through osteoblastic reaction to metastatic deposits, and may be detected on bone scan or cross-sectional imaging in patients with known or suspected malignancy. Osteomalacia (vitamin D deficiency producing undermineralised bone), hyperparathyroidism, and healing fractures all elevate bone ALP. Metastases to the liver itself produce mixed elevation of both hepatic ALP (from direct hepatic infiltration and cholestasis) and bone ALP (from bone deposits), making the pattern potentially complex in patients with malignancy.
Other non-hepatic causes of elevated ALP include: small intestinal ALP elevation after fatty meals (the intestinal isoenzyme rises transiently post-prandially — an artefact that is eliminated by fasting before the blood draw); renal ALP in some forms of chronic kidney disease; and rare congenital hyperphosphatasaemia syndromes. Heart failure with hepatic congestion produces a characteristic ALP pattern — mildly elevated ALP alongside elevated GGT and bilirubin from hepatic venous congestion, often with ALP remaining relatively lower than in biliary obstruction — which reflects the passive congestion of hepatic sinusoids rather than primary biliary pathology. Distinguishing these patterns requires combining the ALP level and GGT result with the clinical history, imaging, and concurrent blood tests — the same systematic approach that applies to all liver function test interpretation. Understanding that an elevated ALP can represent benign physiological variation, important but treatable biliary disease, or a sign of malignancy — and that GGT co-elevation is the key first step in distinguishing hepatic from non-hepatic causes — gives clinicians and patients the framework to navigate a common and clinically important blood test abnormality. The full context of when abnormal liver blood tests including ALP require urgent review is covered in the article on when digestive and liver symptoms need prompt medical attention.
Frequently Asked Questions About the Alkaline Phosphatase Test
My ALP is elevated but my GGT is normal — should I be concerned about my liver?
An elevated ALP with a normal GGT almost always means the elevated ALP is coming from bone rather than the liver or bile ducts. GGT is co-elevated in virtually all hepatobiliary causes of elevated ALP — including bile duct stones, biliary obstruction, primary biliary cholangitis, and primary sclerosing cholangitis — so a normal GGT effectively rules out clinically significant hepatic biliary disease as the source. Bone-origin ALP elevation warrants investigation of bone pathology: in an older adult with moderate elevation, Paget’s disease is the most common cause and can be confirmed with an X-ray of the pelvis and skull. In someone with known or suspected cancer (breast, prostate, lung, or any cancer with bone metastasis risk), elevated bone ALP warrants bone scan or PET-CT to assess for skeletal metastases. If you are an adolescent, pregnant, or in the third trimester of pregnancy, elevated ALP is physiological and requires no bone or liver investigation. The key question your doctor will ask is: does the clinical context fit a physiological explanation, or does it fit a pathological bone cause?
How is ALP monitored in patients on treatment for primary biliary cholangitis?
ALP is the primary biochemical marker for monitoring primary biliary cholangitis (PBC) treatment response. After twelve months of ursodeoxycholic acid (UDCA) therapy, biochemical response is assessed using criteria such as the Paris-II criteria (ALP below 1.5 times the upper limit of normal, AST below 1.5 times ULN, and bilirubin normal) and the Barcelona criteria (ALP reduction to less than forty percent of baseline or to within normal limits). Achieving biochemical response is associated with excellent long-term outcomes comparable to the general population in some studies; failure to achieve response identifies patients who require add-on therapy with obeticholic acid or bezafibrate. Serial ALP measurement every three to six months is therefore standard monitoring in PBC, providing the clearest indication of whether the bile duct inflammation is being controlled. In patients with PBC and advanced fibrosis, ALP normalization may be accompanied by reducing liver stiffness on FibroScan as biliary inflammation is controlled — another marker of disease stability. Understanding how ALP connects to the broader liver disease picture — including symptoms such as fatigue in chronic biliary liver disease and dark urine indicating bilirubin excretion problems — allows patients to track their condition more completely than blood tests alone.
Sources: AASLD — Liver Disease Guidelines · NIDDK — Liver Disease · Mayo Clinic — Alkaline Phosphatase Test
Drug-Induced Cholestasis and ALP Elevation
Drug-induced liver injury (DILI) manifesting as a cholestatic pattern — predominantly elevated ALP and GGT with relatively preserved aminotransferases, often accompanied by raised bilirubin and clinical jaundice — is an important and frequently encountered cause of ALP elevation that requires a careful medication history to identify. Cholestatic DILI is produced by drugs that impair bile secretion at the hepatocyte canalicular membrane (the interface between the hepatocyte and the bile canaliculus), reduce bile acid transport through the biliary system, or directly injure cholangiocytes. Common culprit drugs producing cholestatic or mixed cholestatic-hepatocellular DILI include amoxicillin-clavulanate (one of the most frequent causes of cholestatic DILI in Western countries), flucloxacillin and other isoxazolyl penicillins (particularly associated with prolonged cholestasis lasting weeks to months), macrolide antibiotics (erythromycin, azithromycin), trimethoprim-sulfamethoxazole, antifungals (ketoconazole, itraconazole), chlorpromazine and other phenothiazines, carbamazepine, and anabolic-androgenic steroids. Oestrogen-containing oral contraceptives produce intrahepatic cholestasis through impairment of bile acid transport, more commonly in genetically susceptible individuals (particularly those with underlying ABCB4 or FIC1 gene variants, and those with a history of intrahepatic cholestasis of pregnancy).
The onset of cholestatic DILI is typically within one to eight weeks of starting the causative drug, and resolution may take weeks to months after stopping the agent — much slower than the resolution of hepatocellular DILI, which typically normalises within four to twelve weeks. Flucloxacillin-associated cholestasis is particularly notable for its prolonged course, with ALP and bilirubin sometimes remaining elevated for six to twelve months despite drug cessation, occasionally progressing to ductopenic chronic cholestasis (vanishing bile duct syndrome). This prolonged course can mislead clinicians into investigating for other causes if the drug history is not carefully elicited, emphasizing again the importance of medication review in any patient with unexplained cholestatic ALP elevation. Herbal and dietary supplements — green tea extract, black cohosh, traditional Chinese herbal preparations, and Ayurvedic medicines in particular — are under-recognised causes of cholestatic and mixed DILI, and the same careful history-taking applies. When cholestatic DILI is suspected, the Roussel Uclaf Causality Assessment Method (RUCAM) provides a structured scoring approach for estimating the probability that a given drug or supplement caused the observed liver injury — useful both for clinical decisions and for regulatory pharmacovigilance reporting. The article on jaundice as a visible sign of cholestatic liver disease covers the clinical presentation when cholestatic DILI produces bilirubin elevation sufficient to cause visible yellowing.
GGT in Detail — Sensitivity and Specificity Considerations
Gamma-glutamyl transferase (GGT) deserves specific attention as the companion marker to ALP in distinguishing hepatobiliary from non-hepatic ALP elevation. GGT is synthesised by bile duct epithelial cells, hepatocytes, and kidney tubular cells, and is induced by alcohol, many medications, and hepatocellular damage from virtually any cause — making it highly sensitive for hepatobiliary disease but relatively non-specific as a single marker. Its key clinical utility is precisely this sensitivity: if GGT is normal when ALP is elevated, it effectively excludes all clinically significant hepatobiliary causes of the ALP elevation, redirecting investigation toward bone and other non-hepatic sources. When GGT is elevated alone — without ALP or aminotransferase elevation — it most commonly indicates regular alcohol consumption (GGT normalises within two to six weeks of abstinence and has been used as an abstinence marker in alcohol treatment programmes), obesity-related hepatic steatosis, or medication induction (anticonvulsants such as phenytoin and carbamazepine, rifampicin, and barbiturates all induce GGT without necessarily causing liver injury). Isolated GGT elevation with no other liver test abnormality, in an otherwise well patient, is usually managed with lifestyle advice (alcohol reduction, weight loss) and repeat testing rather than hepatological investigation.
The combination of ALP and GGT elevation in the cholestatic pattern should trigger a systematic investigation beginning with liver ultrasound — the first-line imaging for all patients with unexplained cholestatic liver tests. Ultrasound can identify bile duct dilation (pointing toward extrahepatic obstruction), gallbladder stones (which may be associated with common bile duct stones), hepatic parenchymal changes suggesting underlying cirrhosis, and space-occupying lesions that might compress the bile ducts. If ultrasound is normal or non-diagnostic, MRCP is the next investigation of choice for detailed biliary anatomy — it can identify common bile duct stones, bile duct strictures, and the characteristic bead-on-string appearance of primary sclerosing cholangitis without the radiation exposure or invasive risk of ERCP. Anti-mitochondrial antibody (AMA) testing for primary biliary cholangitis, liver autoimmune panel (ANA, ASMA, anti-LKM, IgG) for autoimmune hepatitis with cholestatic features, and immunoglobulin levels (elevated IgM in PBC, elevated IgG4 in IgG4-related sclerosing cholangitis) complete the non-invasive initial workup for unexplained cholestatic ALP elevation. The article on dark urine and its diagnostic significance explains how the bilirubin elevation that accompanies cholestatic ALP elevation manifests clinically.
ALP in the Context of the Full Liver Function Panel
ALP’s full diagnostic value emerges when it is interpreted alongside the other components of the liver function panel — particularly GGT (for hepatic origin confirmation), ALT and AST (for hepatocellular injury), bilirubin (for excretory function), and albumin and INR (for synthetic function). A purely cholestatic picture — elevated ALP and GGT with near-normal ALT, AST, and albumin, and variable bilirubin — suggests biliary disease or biliary obstruction without significant hepatocellular involvement. A mixed picture — elevated ALP alongside elevated ALT and AST — can occur in drug-induced liver injury (which frequently has mixed hepatocellular-cholestatic features), alcoholic hepatitis (where GGT elevation is a prominent feature), infiltrative liver disease (sarcoidosis, lymphoma, metastases), and granulomatous hepatitis. A predominantly hepatocellular picture — elevated ALT and AST with relatively preserved ALP — occurs in acute viral hepatitis, autoimmune hepatitis, and most cases of MASLD, where the bile duct cells are not the primary target of injury.
In cirrhosis, ALP is typically modestly elevated and may even be within normal limits in some patients — cirrhosis itself does not produce marked ALP elevation unless complicated by biliary disease (PSC-related cirrhosis, cholestatic cirrhosis in PBC) or hepatocellular carcinoma (HCC). HCC can produce marked ALP elevation through two mechanisms: direct intrahepatic biliary obstruction from tumour mass, and production of ALP by the tumour cells themselves (which can express placental isoenzyme — a phenomenon called ectopic ALP production). In patients with cirrhosis who develop a sudden rise in ALP out of proportion to their stable clinical picture, HCC surveillance ultrasound and AFP measurement should be performed to exclude tumour development. Similarly, in patients with jaundice and markedly elevated ALP, cholangiography to exclude cholangiocarcinoma arising on the background of PSC or choledocholithiasis is a critical investigation. The relationship between ALP and specific symptoms that signal biliary pathology — including the itching from bile salt accumulation that often precedes visible jaundice in PBC — demonstrates how the blood test and clinical examination complement each other in cholestatic liver disease diagnosis.
Alkaline phosphatase, often overshadowed by the more frequently discussed ALT and AST, is in fact the most distinctive liver test for identifying cholestatic and biliary disease — the conditions that most frequently require intervention (ERCP for stones, surgery for malignant obstruction, UDCA and add-on therapies for autoimmune biliary disease). Recognising the pattern of elevated ALP, confirming its hepatic origin through GGT, and following the systematic investigation pathway toward imaging and specific autoimmune or cancer testing is the clinical response that these blood test results call for. Understanding this framework — and knowing that an elevated ALP does not always mean liver disease, and that the GGT result is the pivotal first interpretation step — provides patients and clinicians with the tools to respond appropriately to one of the most commonly encountered abnormal liver function test patterns in routine blood panels.
I had elevated ALP for months and was worried about my liver. My GGT was normal the whole time. This article finally explained why my doctor wasn’t concerned — the bone Paget’s diagnosis came back positive on X-ray and suddenly it all made sense. The GGT is the key I didn’t know to look for.
Ruth, thank you for sharing that — your experience actually illustrates the most important practical point in interpreting an elevated ALP: the GGT test is the first step. When GGT is normal and ALP is elevated, the liver is almost never the source, and investigations should pivot to bone causes. Paget’s disease is very manageable once diagnosed, and knowing it wasn’t a liver problem all along must have been a significant relief. We’re glad the article helped connect those dots.
The section on amoxicillin-clavulanate as a common cause of cholestatic DILI is something that comes up frequently in GP practice. Patients often don’t connect the antibiotic they had six weeks ago with the elevated ALP they’re seeing now. Good to have this clearly written up in one place.